Press release
Chronic Idiopathic Constipation Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
Chronic Idiopathic Constipation Clinical Trials
"Chronic Idiopathic Constipation Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Idiopathic Constipation Market.
The Chronic Idiopathic Constipation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Chronic Idiopathic Constipation Pipeline Report:
• Chronic Idiopathic Constipation Companies across the globe are diligently working toward developing novel Chronic Idiopathic Constipation treatment therapies with a considerable amount of success over the years.
• Chronic Idiopathic Constipation companies working in the treatment market are ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others, are developing therapies for the Chronic Idiopathic Constipation treatment
• Emerging Chronic Idiopathic Constipation therapies in the different phases of clinical trials are- LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others are expected to have a significant impact on the Chronic Idiopathic Constipation market in the coming years.
• In December 2024, NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults, has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its RED (Rectal Expulsion Device). This approval enables NeurAxis to commercially market the device for testing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia, particularly those who are unlikely to see improvement with increased laxative use.
• In November 2024, Ironwood Pharmaceuticals (Nasdaq: IRWD), a member of the S&P SmallCap 600®, is a leading gastrointestinal (GI) healthcare company dedicated to improving the treatment of GI diseases and setting new standards of care for GI patients. As pioneers in the development of LINZESS® (linaclotide), we are proud to lead the U.S. branded prescription market for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Chronic Idiopathic Constipation Overview
Chronic Idiopathic Constipation (CIC) is a long-term condition characterized by infrequent, difficult, or incomplete bowel movements without an identifiable medical cause. It is a common functional gastrointestinal disorder affecting millions worldwide, particularly older adults and women. Unlike constipation caused by underlying conditions such as neurological disorders or medication side effects, Chronic Idiopathic Constipation has no known structural or biochemical cause.
Symptoms of Chronic Idiopathic Constipation include straining during bowel movements, hard or lumpy stools, a sensation of incomplete evacuation, and reduced bowel movement frequency (less than three per week). These symptoms can significantly impact a person's quality of life, leading to discomfort, bloating, and social distress. The exact cause of Chronic Idiopathic Constipation remains unclear, but factors such as altered gut motility, nerve dysfunction, and changes in gut microbiota may contribute.
Chronic Idiopathic Constipation Diagnosis is based on symptom criteria, such as the Rome IV criteria, and the exclusion of secondary causes. Chronic Idiopathic Constipation Treatment includes dietary modifications (high-fiber diet, increased water intake), lifestyle changes (regular exercise), over-the-counter laxatives, and prescription medications like secretagogues or prokinetic agents. In severe cases, biofeedback therapy or other advanced treatments may be recommended.
Managing Chronic Idiopathic Constipation requires a tailored approach to improve bowel function and enhance the patient's overall well-being.
Get a Free Sample PDF Report to know more about Chronic Idiopathic Constipation Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Chronic Idiopathic Constipation Drugs Under Different Phases of Clinical Development Include:
• A3309: Albireo
• AJG555: EA Pharma Co., Ltd.
• linaclotide: Astellas Pharma Inc
• KWA-0711: Kissei Pharmaceutical Co., Ltd.
• Tegaserod: Novartis
• TD-5108: Theravance Biopharma
• YKP10811: SK Life Science, Inc.
• prucalopride: Movetis
• KWA-0711: Kissei Pharmaceutical Co., Ltd
• PEG 4000 (Forlax®): Ipsen
Chronic Idiopathic Constipation Pipeline Therapeutics Assessment
• Chronic Idiopathic Constipation Assessment by Product Type
• Chronic Idiopathic Constipation By Stage and Product Type
• Chronic Idiopathic Constipation Assessment by Route of Administration
• Chronic Idiopathic Constipation By Stage and Route of Administration
• Chronic Idiopathic Constipation Assessment by Molecule Type
• Chronic Idiopathic Constipation by Stage and Molecule Type
DelveInsight's Chronic Idiopathic Constipation Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Chronic Idiopathic Constipation product details are provided in the report. Download the Chronic Idiopathic Constipation pipeline report to learn more about the emerging Chronic Idiopathic Constipation therapies at:
https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Chronic Idiopathic Constipation Therapeutics Market include:
Key companies developing therapies for Chronic Idiopathic Constipation are - Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Abbott, AstraZeneca PLC, Pfizer Inc, Takeda Pharma, and others.
Chronic Idiopathic Constipation Pipeline Analysis:
The Chronic Idiopathic Constipation pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Idiopathic Constipation with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Idiopathic Constipation Treatment.
Chronic Idiopathic Constipation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Idiopathic Constipation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Idiopathic Constipation market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Idiopathic Constipation drugs and therapies- https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Chronic Idiopathic Constipation Pipeline Market Drivers
• Rising Prevalence of Chronic Idiopathic Constipation, Aging Population, Advancements in Drug Development, Increasing Awareness and Diagnosis Rates, Regulatory Approvals and Pipeline Expansion, Growing Investment in Gastrointestinal Research, are some of the important factors that are fueling the Chronic Idiopathic Constipation Market.
Chronic Idiopathic Constipation Pipeline Market Barriers
• However, High Clinical Trial Failure Rates, Side Effects of Available Treatments, Limited Patient Compliance, High Development Costs, Generic Competition, Regulatory Challenges, and other factors are creating obstacles in the Chronic Idiopathic Constipation Market growth.
Scope of Chronic Idiopathic Constipation Pipeline Drug Insight
• Coverage: Global
• Key Chronic Idiopathic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
• Key Chronic Idiopathic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others
• Chronic Idiopathic Constipation Therapeutic Assessment: Chronic Idiopathic Constipation current marketed and Chronic Idiopathic Constipation emerging therapies
• Chronic Idiopathic Constipation Market Dynamics: Chronic Idiopathic Constipation market drivers and Chronic Idiopathic Constipation market barriers
Request for Sample PDF Report for Chronic Idiopathic Constipation Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chronic-idiopathic-constipation-cic-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Chronic Idiopathic Constipation Report Introduction
2. Chronic Idiopathic Constipation Executive Summary
3. Chronic Idiopathic Constipation Overview
4. Chronic Idiopathic Constipation- Analytical Perspective In-depth Commercial Assessment
5. Chronic Idiopathic Constipation Pipeline Therapeutics
6. Chronic Idiopathic Constipation Late Stage Products (Phase II/III)
7. Chronic Idiopathic Constipation Mid Stage Products (Phase II)
8. Chronic Idiopathic Constipation Early Stage Products (Phase I)
9. Chronic Idiopathic Constipation Preclinical Stage Products
10. Chronic Idiopathic Constipation Therapeutics Assessment
11. Chronic Idiopathic Constipation Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Idiopathic Constipation Key Companies
14. Chronic Idiopathic Constipation Key Products
15. Chronic Idiopathic Constipation Unmet Needs
16 . Chronic Idiopathic Constipation Market Drivers and Barriers
17. Chronic Idiopathic Constipation Future Perspectives and Conclusion
18. Chronic Idiopathic Constipation Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Idiopathic Constipation Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight here
News-ID: 3888478 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
